U.S. Markets open in 2 hrs 43 mins

InterMune Slumps: ITMN Falls 14.9% in Session

Zacks Equity Research

InterMune Inc. (ITMN) saw a big move last session, as the company’s shares fell by almost 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session.

The stock has been trending flat since Feb 3, but witnessed a sharp uptrend on Feb 24. On Feb 25 the stock plunged again.

Although this slump was obviously disappointing, this biotechnology company has seen 1 positive revisions and its current year earnings consensus has remained flat over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for ITMN. So make sure to keep an eye on this stock going forward to see if yesterday’s price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

ITMN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the biopharmaceutical sector include Alexion Pharmaceuticals, Inc. (ALXN), Biogen Idec Inc. (BIIB) and Acceleron Pharma, Inc. (XLRN). While Alexion holds a Zacks Rank #1 (Strong Buy), Biogen and Acceleron carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

INTERMUNE INC (ITMN): Free Stock Analysis Report


BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

ACCELERON PHARMA INC (XLRN): Free Stock Analysis Report

Zacks Investment Research